Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1998 Feb;64(2):162–165. doi: 10.1136/jnnp.64.2.162

Circulating transforming growth factor beta 1 (TGF-β1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function

A Creange 1, L Belec 1, B Clair 1, J Degos 1, J Raphael 1, R Gherardi 1
PMCID: PMC2169967  PMID: 9489524

Abstract

OBJECTIVE—To delineate the possible implication of the immunosuppressive cytokine transforming growth factor beta 1 (TGF-β1) in the pathogenesis of Guillain-Barré syndrome. Guillain-Barré syndrome is a disorder that may implicate cytokines in its pathogenesis. TGF-β1 is a potent anti-inflammatory cytokine occasionally shown to be regulated in the course of demyelinating disorders.
METHODS—The study measured circulating proinflammatory and anti-inflammatory cytokines from the progressing phase to early recovery in patients with Guillain-Barré syndrome. Plasma concentrations of TNF-α, IL-1β, IL-2, IL-4, IL-6, IL-10, and TGF-β1 were prospectively evaluated in 15 patients with Guillain-Barré syndrome every three days for the first 15 days after admission to hospital, and in 15 controls with non-inflammatory neurological diseases.
RESULTS—Concentrations of TGF-β1 in plasma were decreased in 13/15 patients (87 %) at day 1, remained low during progression and the plateau of paralysis (days 1-10), and then progressively increased up to control concentrations during early recovery (days 12-15). Concentrations of plasma TGF-β1 correlated positively with motor function, the lowest values being found in the most disabled patients. Concentrations of plasma TGF-β1 were decreased before any treatment, and during treatment by either plasma exchange or intravenous immunoglobulins, plasma exchange being associated with a more pronounced decrease in TGF-β1 at day 7. Circulating TNF-α concentrations were raised, as previously reported, when other cytokines were either randomly increased (IL-2, IL-6), or undetectable (IL-1, IL-4, IL-7, IL-10).
CONCLUSIONS—Down regulation of TGF-β1 in the early course of Guillain-Barré syndrome could participate in neural inflammation.



Full Text

The Full Text of this article is available as a PDF (132.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alderson M. R., Tough T. W., Ziegler S. F., Grabstein K. H. Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med. 1991 Apr 1;173(4):923–930. doi: 10.1084/jem.173.4.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. AyanlarBatuman O., Ferrero A. P., Diaz A., Jimenez S. A. Regulation of transforming growth factor-beta 1 gene expression by glucocorticoids in normal human T lymphocytes. J Clin Invest. 1991 Nov;88(5):1574–1580. doi: 10.1172/JCI115469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chalazonitis A., Kalberg J., Twardzik D. R., Morrison R. S., Kessler J. A. Transforming growth factor beta has neurotrophic actions on sensory neurons in vitro and is synergistic with nerve growth factor. Dev Biol. 1992 Jul;152(1):121–132. doi: 10.1016/0012-1606(92)90162-a. [DOI] [PubMed] [Google Scholar]
  4. Chen Y., Kuchroo V. K., Inobe J., Hafler D. A., Weiner H. L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994 Aug 26;265(5176):1237–1240. doi: 10.1126/science.7520605. [DOI] [PubMed] [Google Scholar]
  5. Childs C. B., Proper J. A., Tucker R. F., Moses H. L. Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci U S A. 1982 Sep;79(17):5312–5316. doi: 10.1073/pnas.79.17.5312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Christ M., McCartney-Francis N. L., Kulkarni A. B., Ward J. M., Mizel D. E., Mackall C. L., Gress R. E., Hines K. L., Tian H., Karlsson S. Immune dysregulation in TGF-beta 1-deficient mice. J Immunol. 1994 Sep 1;153(5):1936–1946. [PubMed] [Google Scholar]
  7. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol. 1978 Jun;3(6):565–566. doi: 10.1002/ana.410030628. [DOI] [PubMed] [Google Scholar]
  8. Créange A., Bélec L., Clair B., Raphaël J. C., Gherardi R. K. Circulating tumor necrosis factor (TNF)-alpha and soluble TNF-alpha receptors in patients with Guillain-Barré syndrome. J Neuroimmunol. 1996 Aug;68(1-2):95–99. doi: 10.1016/0165-5728(96)00075-6. [DOI] [PubMed] [Google Scholar]
  9. Czarniecki C. W., Chiu H. H., Wong G. H., McCabe S. M., Palladino M. A. Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol. 1988 Jun 15;140(12):4217–4223. [PubMed] [Google Scholar]
  10. Dubinett S. M., Huang M., Dhanani S., Wang J., Beroiza T. Down-regulation of macrophage transforming growth factor-beta messenger RNA expression by IL-7. J Immunol. 1993 Dec 15;151(12):6670–6680. [PubMed] [Google Scholar]
  11. Einheber S., Hannocks M. J., Metz C. N., Rifkin D. B., Salzer J. L. Transforming growth factor-beta 1 regulates axon/Schwann cell interactions. J Cell Biol. 1995 Apr;129(2):443–458. doi: 10.1083/jcb.129.2.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gamble J. R., Vadas M. A. Endothelial cell adhesiveness for human T lymphocytes is inhibited by transforming growth factor-beta 1. J Immunol. 1991 Feb 15;146(4):1149–1154. [PubMed] [Google Scholar]
  13. Gherardi R. K., Bélec L., Soubrier M., Malapert D., Zuber M., Viard J. P., Intrator L., Degos J. D., Authier F. J. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood. 1996 Feb 15;87(4):1458–1465. [PubMed] [Google Scholar]
  14. Gherardi R. K., Chouaïb S., Malapert D., Bélec L., Intrator L., Degos J. D. Early weight loss and high serum tumor necrosis factor-alpha levels in polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes syndrome. Ann Neurol. 1994 Apr;35(4):501–505. doi: 10.1002/ana.410350423. [DOI] [PubMed] [Google Scholar]
  15. Griffin J. W., George R., Ho T. Macrophage systems in peripheral nerves. A review. J Neuropathol Exp Neurol. 1993 Nov;52(6):553–560. doi: 10.1097/00005072-199311000-00001. [DOI] [PubMed] [Google Scholar]
  16. Guénard V., Gwynn L. A., Wood P. M. Transforming growth factor-beta blocks myelination but not ensheathment of axons by Schwann cells in vitro. J Neurosci. 1995 Jan;15(1 Pt 1):419–428. doi: 10.1523/JNEUROSCI.15-01-00419.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Harpel J. G., Metz C. N., Kojima S., Rifkin D. B. Control of transforming growth factor-beta activity: latency vs. activation. Prog Growth Factor Res. 1992;4(4):321–335. doi: 10.1016/0955-2235(92)90014-9. [DOI] [PubMed] [Google Scholar]
  18. Hartung H. P., Hughes R. A., Taylor W. A., Heininger K., Reiners K., Toyka K. V. T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology. 1990 Feb;40(2):215–218. doi: 10.1212/wnl.40.2.215. [DOI] [PubMed] [Google Scholar]
  19. Hartung H. P., Reiners K., Schmidt B., Stoll G., Toyka K. V. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol. 1991 Jul;30(1):48–53. doi: 10.1002/ana.410300110. [DOI] [PubMed] [Google Scholar]
  20. Hughes R. A., Newsom-Davis J. M., Perkin G. D., Pierce J. M. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978 Oct 7;2(8093):750–753. doi: 10.1016/s0140-6736(78)92644-2. [DOI] [PubMed] [Google Scholar]
  21. Johns L. D., Flanders K. C., Ranges G. E., Sriram S. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1. J Immunol. 1991 Sep 15;147(6):1792–1796. [PubMed] [Google Scholar]
  22. Jung S., Schluesener H. J., Schmidt B., Fontana A., Toyka K. V., Hartung H. P. Therapeutic effect of transforming growth factor-beta 2 on actively induced EAN but not adoptive transfer EAN. Immunology. 1994 Dec;83(4):545–551. [PMC free article] [PubMed] [Google Scholar]
  23. Keramidas M., Chambaz E. M., Feige J. J. Inhibition of adrenocortical steroidogenesis by alpha 2-macroglobulin is caused by associated transforming growth factor beta. Mol Cell Endocrinol. 1992 Apr;84(3):243–251. doi: 10.1016/0303-7207(92)90035-5. [DOI] [PubMed] [Google Scholar]
  24. Kiefer R., Funa K., Schweitzer T., Jung S., Bourde O., Toyka K. V., Hartung H. P. Transforming growth factor-beta 1 in experimental autoimmune neuritis. Cellular localization and time course. Am J Pathol. 1996 Jan;148(1):211–223. [PMC free article] [PubMed] [Google Scholar]
  25. Kiefer R., Streit W. J., Toyka K. V., Kreutzberg G. W., Hartung H. P. Transforming growth factor-beta 1: a lesion-associated cytokine of the nervous system. Int J Dev Neurosci. 1995 Jun-Jul;13(3-4):331–339. doi: 10.1016/0736-5748(94)00074-d. [DOI] [PubMed] [Google Scholar]
  26. Koski C. L., Gratz E., Sutherland J., Mayer R. F. Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barré syndrome. Ann Neurol. 1986 Jun;19(6):573–577. doi: 10.1002/ana.410190609. [DOI] [PubMed] [Google Scholar]
  27. Lefaucheur J. P., Gjata B., Lafont H., Sebille A. Angiogenic and inflammatory responses following skeletal muscle injury are altered by immune neutralization of endogenous basic fibroblast growth factor, insulin-like growth factor-1 and transforming growth factor-beta 1. J Neuroimmunol. 1996 Oct;70(1):37–44. doi: 10.1016/s0165-5728(96)00099-9. [DOI] [PubMed] [Google Scholar]
  28. Maimone D., Annunziata P., Simone I. L., Livrea P., Guazzi G. C. Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol. 1993 Aug;47(1):55–61. doi: 10.1016/0165-5728(93)90284-6. [DOI] [PubMed] [Google Scholar]
  29. Miller A., Lider O., Roberts A. B., Sporn M. B., Weiner H. L. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):421–425. doi: 10.1073/pnas.89.1.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Redford E. J., Hall S. M., Smith K. J. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain. 1995 Aug;118(Pt 4):869–878. doi: 10.1093/brain/118.4.869. [DOI] [PubMed] [Google Scholar]
  31. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Lüer W., Poser S. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology. 1994 Aug;44(8):1523–1526. doi: 10.1212/wnl.44.8.1523. [DOI] [PubMed] [Google Scholar]
  32. Roberts A. B., Sporn M. B. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors. 1993;8(1):1–9. doi: 10.3109/08977199309029129. [DOI] [PubMed] [Google Scholar]
  33. Rogister B., Delrée P., Leprince P., Martin D., Sadzot C., Malgrange B., Munaut C., Rigo J. M., Lefebvre P. P., Octave J. N. Transforming growth factor beta as a neuronoglial signal during peripheral nervous system response to injury. J Neurosci Res. 1993 Jan;34(1):32–43. doi: 10.1002/jnr.490340105. [DOI] [PubMed] [Google Scholar]
  34. Sharief M. K., McLean B., Thompson E. J. Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome. Ann Neurol. 1993 Jun;33(6):591–596. doi: 10.1002/ana.410330606. [DOI] [PubMed] [Google Scholar]
  35. Sharp B. M., Matta S. G., Peterson P. K., Newton R., Chao C., Mcallen K. Tumor necrosis factor-alpha is a potent ACTH secretagogue: comparison to interleukin-1 beta. Endocrinology. 1989 Jun;124(6):3131–3133. doi: 10.1210/endo-124-6-3131. [DOI] [PubMed] [Google Scholar]
  36. Shull M. M., Ormsby I., Kier A. B., Pawlowski S., Diebold R. J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992 Oct 22;359(6397):693–699. doi: 10.1038/359693a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Shull S., Meisler N., Absher M., Phan S., Cutroneo K. Glucocorticoid-induced down regulation of transforming growth factor-beta 1 in adult rat lung fibroblasts. Lung. 1995;173(2):71–78. doi: 10.1007/BF02981467. [DOI] [PubMed] [Google Scholar]
  38. Sindern E., Schweppe K., Ossege L. M., Malin J. P. Potential role of transforming growth factor-beta 1 in terminating the immune response in patients with Guillain-Barré syndrome. J Neurol. 1996 Mar;243(3):264–268. doi: 10.1007/BF00868524. [DOI] [PubMed] [Google Scholar]
  39. Taylor W. A., Hughes R. A. T lymphocyte activation antigens in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol. 1989 Sep;24(1-2):33–39. doi: 10.1016/0165-5728(89)90095-7. [DOI] [PubMed] [Google Scholar]
  40. Tsunawaki S., Sporn M., Ding A., Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature. 1988 Jul 21;334(6179):260–262. doi: 10.1038/334260a0. [DOI] [PubMed] [Google Scholar]
  41. Vodovotz Y., Bogdan C., Paik J., Xie Q. W., Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J Exp Med. 1993 Aug 1;178(2):605–613. doi: 10.1084/jem.178.2.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Zhu J., Mix E., Olsson T., Link H. Cellular mRNA expression of interferon-gamma, IL-4 and transforming growth factor-beta (TGF-beta) by rat mononuclear cells stimulated with peripheral nerve myelin antigens in experimental allergic neuritis. Clin Exp Immunol. 1994 Nov;98(2):306–312. doi: 10.1111/j.1365-2249.1994.tb06142.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES